Pharmacokinetic comparisons between liposome formulation and non-liposome formulation of omega-3 fatty acids: a randomized clinical study

This study evaluated the effect of a liposomal omega-3 formulation (Liposomal ABMax Omega-3) on the extent of absorption of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) compared with conventional ethyl ester (EE) and re-esterified triglyceride (rTG) formulations. In a randomized, double-blinded, parallel, active-controlled clinical study, 45 healthy adults received a single oral dose of (1,800 mg total) liposomal omega-3 (Liposomal ABMax Omega-3), EE omega-3, or rTG omega-3.

Baseline-corrected serum concentrations of EPA and DHA were measured up to 24 h post-dose. Pharmacokinetic parameters were derived using noncompartmental methods, with incremental AUC (iAUC) as the primary endpoint. Liposomal omega-3 (Liposomal ABMax Omega-3) resulted in significantly higher baseline-corrected iAUC for DHA and EPA+DHA than the conventional EE and rTG formulations.